MX2019013157A - Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. - Google Patents

Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos.

Info

Publication number
MX2019013157A
MX2019013157A MX2019013157A MX2019013157A MX2019013157A MX 2019013157 A MX2019013157 A MX 2019013157A MX 2019013157 A MX2019013157 A MX 2019013157A MX 2019013157 A MX2019013157 A MX 2019013157A MX 2019013157 A MX2019013157 A MX 2019013157A
Authority
MX
Mexico
Prior art keywords
fragment
sequence
pharmaceutical compositions
terminal
manf
Prior art date
Application number
MX2019013157A
Other languages
English (en)
Inventor
Mart Saarma
Mikko Airavaara
Merja Voutilainen
Li Ying Yu
Maria Lindahl
Original Assignee
Helsingin Yliopisto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsingin Yliopisto filed Critical Helsingin Yliopisto
Publication of MX2019013157A publication Critical patent/MX2019013157A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona una secuencia de un fragmento de CDNF C-terminal, o una secuencia que tiene por lo menos 90 % de homología con dicha secuencia. El fragmento CDNF C-terminal protege a las neuronas, neuronas motrices y neuronas dopaminérgicas con RE estresado, y el fragmento es capaz de penetrar la membrana celular neuronal y también la barrera hematoencefálica. La presente invención proporciona, además, dicho fragmento y composiciones farmacéuticas que comprenden dicho fragmento para usarse en el tratamiento de enfermedades y trastornos degenerativos que incluyen enfermedades del sistema nervioso central, diabetes y trastornos retinianos. La presente invención también proporciona una secuencia de un fragmento de MANF C-terminal, o una secuencia que tiene por lo menos 90 % de homología con dicha secuencia, y composiciones farmacéuticas que comprenden dicho fragmento de MANF para usarse en el tratamiento de enfermedades y trastornos degenerativos que incluyen enfermedades del sistema nervioso central, diabetes y trastornos retinianos.
MX2019013157A 2017-05-04 2018-05-04 Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. MX2019013157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20175392 2017-05-04
PCT/FI2018/050332 WO2018202957A1 (en) 2017-05-04 2018-05-04 C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof

Publications (1)

Publication Number Publication Date
MX2019013157A true MX2019013157A (es) 2020-08-03

Family

ID=62218004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013157A MX2019013157A (es) 2017-05-04 2018-05-04 Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos.

Country Status (12)

Country Link
US (1) US20200071372A1 (es)
EP (1) EP3619227A1 (es)
JP (1) JP7384672B2 (es)
KR (1) KR20200003889A (es)
CN (1) CN110831960A (es)
AU (1) AU2018263087B2 (es)
BR (1) BR112019023116A2 (es)
CA (1) CA3062241A1 (es)
MX (1) MX2019013157A (es)
RU (1) RU2019136495A (es)
SG (1) SG11201910183SA (es)
WO (1) WO2018202957A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010301A (es) * 2018-03-29 2020-10-20 Helsingin Yliopisto Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos.
EP3838345A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Macrocyclic peptides
EP3838912A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
WO2021160938A1 (en) 2020-02-13 2021-08-19 Herantis Pharma Oyj Systemic administration of a pharmaceutical composition comprising cdnf or manf polypeptide for use in the treatment of reperfusion injury
CN117018231B (zh) * 2023-08-16 2024-05-10 科辉智药(深圳)新药研究中心有限公司 用于治疗神经病变的基因疗法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CA2441327A1 (en) * 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
JP5236488B2 (ja) 2005-12-14 2013-07-17 ハーモ ファーマ エルテーデー. 新規な神経栄養因子タンパク質およびその用途
FI20080326A0 (fi) * 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
FI20115870A0 (fi) 2011-09-05 2011-09-05 Urmas Arumaee Neuroprotektiiviset soluihin tunkeutuvat peptidit
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
WO2015149005A1 (en) * 2014-03-28 2015-10-01 Buck Institute For Research On Aging Methods and compositions for modulating the immune system
WO2016057579A1 (en) 2014-10-06 2016-04-14 Amarantus Bioscience Holdings, Inc. Methods and compositions for treating retinal disorders

Also Published As

Publication number Publication date
CA3062241A1 (en) 2018-11-08
SG11201910183SA (en) 2019-11-28
JP2020518261A (ja) 2020-06-25
BR112019023116A2 (pt) 2020-07-28
WO2018202957A1 (en) 2018-11-08
AU2018263087A1 (en) 2019-11-28
AU2018263087B2 (en) 2021-12-16
US20200071372A1 (en) 2020-03-05
EP3619227A1 (en) 2020-03-11
CN110831960A (zh) 2020-02-21
KR20200003889A (ko) 2020-01-10
RU2019136495A (ru) 2021-06-04
JP7384672B2 (ja) 2023-11-21

Similar Documents

Publication Publication Date Title
MX2019013157A (es) Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos.
MX2018010693A (es) Compuestos biciclicos para diagnostico y terapia.
BR112019010646A2 (pt) métodos de tratamento de condições inflamatórias
BR112012020953A2 (pt) produto, uso do mesmo, metodo para prevencao e/ou tratamento de fibrose corneana ou opacidade corneana e composicao farmaceutica oftalmica
WO2017062456A3 (en) Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
PH12020500573A1 (en) 1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer`s disease
BR112017014332A2 (pt) métodos de tratamento de doenças retinianas
AU2016249140A8 (en) Anti-PACAP antibodies and uses thereof
MX2009012919A (es) Tratamiento terapeutico para el sindrome metabolico, diabetes tipo 2, obesidad, o prediabetes.
EP3712264A8 (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
MX2017000378A (es) ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS.
MX2020010301A (es) Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos.
BR112022013843A2 (pt) Método de diferenciação de células neurais e composições relacionadas e métodos de uso
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
MX2021000954A (es) Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales.
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
EP3937937A4 (en) TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH MITOCHONDRIA, INCLUDING THEIR SYMPTOMS USING PRIDOPIDINE
MX2015008555A (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
WO2014053110A3 (de) Peptide zur behandlung und frühdiagnose von morbus alzheimer und anderer tauopathien
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112017008734A2 (pt) acelerador de produção de proteína tau e agente preventivo ou terapêutico e composição alimentícia preventiva ou terapêutica para doenças causadas por deficiência de proteína tau
EP3639854A4 (en) MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF
BR112018001267A2 (pt) método de diagnosticar asma, uso de um antagonista do receptor de crth2, produto de fármaco, e, kit
MX2021009326A (es) Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.